| Name | Title | Contact Details |
|---|
Kalmar is a Finland-based company that designs and distributes open automation systems for cargo container handling applications in ports and terminals.
Kaufman Dolowich LLP is a nationally recognized litigation law firm that has been serving the business and insurance communities since 1986. With 13 offices across the United States, Bermuda, and the United Kingdom, the firm has expanded from a boutique labor and employment practice into a comprehensive legal service provider. It offers a wide range of services, including labor and employment law, insurance coverage and litigation, professional liability, construction law, and more. The firm is known for its client-centered approach, focusing on developing innovative and cost-effective legal strategies tailored to various industries and complex legal matters. Kaufman Dolowichs attorneys are recognized leaders in their fields, often sharing their expertise at national conferences. The firm has a diverse clientele, including businesses and insurance carriers of all sizes, and has received accolades for its workplace culture, including multiple Mansfield Certification recognitions and being named among the “Best Companies to Work For” by U.S. News & World Report.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MS Transverse Insurance Group is a property and casualty program carrier based in Princeton, New Jersey. As a subsidiary of Mitsui Sumitomo Insurance Group and part of MS&AD Insurance Group Holdings, it operates as a hybrid fronting carrier. Founded in 2018, the company specializes in program administration, reinsurance partnerships, and alternative capital solutions, serving as a link between reinsurers, program administrators, and Managing General Agents (MGAs). The company offers a range of services, including program administration for niche risks, reinsurance solutions with over 100 reinsurer relationships, flexible risk retention structures, and fronting services that ensure regulatory compliance and claims management. MS Transverse is recognized for its strong financial standing, holding an A (Excellent) rating from A.M. Best, and has been named Fronting Carrier of the Year in 2022 and 2024. With offices in New York, New Jersey, and Texas, it ranks among the top 10 U.S. fronting carriers by direct premiums written.